139,811 Shares of Halozyme Therapeutics, Inc. $HALO Bought by Context Capital Management LLC

Context Capital Management LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 139,811 shares of the biopharmaceutical company’s stock, valued at approximately $15,435,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics during the second quarter worth about $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics during the second quarter valued at about $196,540,000. Jupiter Topco LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $105,570,000. Caisse de depot et placement du Quebec acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $83,940,000. Finally, Congress Asset Management Co. raised its holdings in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $83,995,132. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director directly owned 53,609 shares of the company’s stock, valued at approximately $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 124,226 shares of company stock worth $13,370,893 over the last ninety days. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on HALO shares. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a research report on Friday, October 16th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $95.00 to $110.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.73.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $102.98 on Wednesday. The firm has a market cap of $11.74 billion, a P/E ratio of 18.48, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. The firm’s 50-day simple moving average is $115.07 and its 200-day simple moving average is $85.05. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $134.00. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same quarter in the prior year, the business posted $1.72 earnings per share. The company’s quarterly revenue was up 39.1% compared to the same quarter last year. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.